Head-to-head · WeighScore
EverSlim vs Zealthy
The verdict
EverSlim takes it — 75.8/100 to 46.7/100.
EverSlim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EverSlim is a US telehealth program offering doctor-prescribed, compounded GLP-1 weight-loss medication delivered to your door.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | EverSlim | Zealthy |
|---|---|---|
| WeighScore | 75.8/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #54 | #496 |
| Semaglutide | $127/mo | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $183/mo | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #54 · C
Strengths
- Transparent flat pricing from 127 dollars a month for compounded semaglutide; medication, provider visit, and shipping included with no insurance.
- Names its pharmacy partners (EPIQ Scripts, Foothills, Emerald) and DrTelx medical group; LegitScript-approved and NABP-accredited.
- Available in all 50 states and DC, with asynchronous care in 44 states and live-visit access in the rest.
- Offers both semaglutide and tirzepatide, plus care-team messaging between visits.
Where it loses points
- Compounded medications are not FDA-approved, and no brand-name Wegovy, Ozempic, or Zepbound options are offered.
- Site discloses that some imagery and content may be AI-generated and some ad figures are actors, not real clinicians.
- Newer brand with limited independent, third-party review history.
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.